Galapagos NV (AMS: GLPG)
Netherlands
· Delayed Price · Currency is EUR | Market Cap | 1.64B |
| Revenue (ttm) | 260.09M |
| Net Income (ttm) | 206.33M |
| Shares Out | 65.90M |
| EPS (ttm) | 3.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 132,242 |
| Open | 24.44 |
| Previous Close | 24.94 |
| Day's Range | 23.66 - 24.74 |
| 52-Week Range | 22.00 - 39.00 |
| Beta | 0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2024 |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
Financial StatementsNews
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Mechelen, Belgium; November 5, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66 th Americ...
Galapagos NV 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Galapagos NV in conjunction with their 2024 Q3 earnings call.
Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ETCompany ParticipantsSofie Van Gijsel - Head of IRPaul Stoffels -...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
Webcast presentation on October 31, 2024, at 1 3 :00 CET / 8:00 am ET, www.glpg.com
EcoR1 Capital, LLC Increases Stake in Galapagos NV
EcoR1 Capital, LLC Increases Stake in Galapagos NV
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director...
Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area
SAN DIEGO--(BUSINESS WIRE)--Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO) member of Blood Centers of America (BCA), today announced that it has been selected...
Galapagos receives transparency notification from EcoR1 Capital
Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.
Galapagos receives transparency notification from EcoR1 Capital
Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.
Galapagos receives transparency notification from FMR LLC
Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Galapagos up 10% as major shareholder intends to talk about strategy
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Galapagos NV (NASDAQ: GLPG) stock is trading higher on Monday as Ecor1 Capital reported a 9.9% stake in the European biotech firm in a 13D filing . EcoR1 Capital is now planning to talk to the Belgia...
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 150 points on Monday. Shares of Galapagos NV (NASDAQ: GLPG) rose sharply during Monday's session after Ecor1 Capital reported a...
Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond
Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with rrNHL. Read more on GLPG stock here.
Galapagos gains after FDA nod for lymphoma trial
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has ...
Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG) Q2 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Sofie Van Gijsel - Head of Investor Relations Paul Stoffels - Chair of the Board and Chief E...
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
BridGene Eligible to Receive Up to $15 9 Million in Total Payments SAN JOSE, Calif. , Aug. 1, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for tra...
Galapagos reports half-year 2024 financial results and provides second quarter business update
Webcast presentation with management on 2 August 2024, at 14:00 CET / 8:00 AM ET, www.glpg.com
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T ...
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc...
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized ma...
Galapagos creates new subscription right plans
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new su...
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
Mechelen, Belgium; 15 May 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decen...